Blepharospasm Patient Survey for Patients With Blepharospasm

The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blepharospasm Eye Diseases Eyelid Diseases

Age range

18 year–81 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Merz Investigative Site #0007, Fountain Valley, California, United States

About this study

This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female subject aged > 18 years and < 81 years
Documented clinical diagnosis of blepharospasm
Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA

Exclusion criteria

Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles

Treatment and study plan

No intervention- only one time survey

Other

Primary outcomes

Botulinum Toxin Treatment Information

Time frame: This is a single, structured interview about experiences with Botulinum Toxins

The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)

Sponsors and collaborators

Lead sponsor

Merz Pharmaceuticals GmbH

Industry

Collaborators

Merz North America, Inc.

Registry information

Official study title

Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Sep 17, 2012
Registry last updated: Oct 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed